Biotech's Rapid Response
to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance
Stocks Mentitoned: (Nasdaq:
$AEMD), (NASDAQ:$SNGX), (NASDAQ: $REGN), (NASDAQ:$MRNA)
(Investorideas.com
Newswire) Investorideas.com, a leading investment platform for retail investors
releases an editorial snapshot on biotech and medical tech stocks announcing
potential treatments and vaccines for the 2026 Ebola virus outbreak.
According
to a recent ABC
news headline - “France confirms 1st
Ebola case linked to DRC as UN warns outbreak is fastest-growing in Africa's
history. The outbreak has led to more than 1,000 cases and more than 260
deaths.”
UN
news reports – “Ebola has been spreading at
unprecedented speed in the eastern Democratic Republic of the Congo (DRC),
bringing risk and fear into people’s daily lives, UN humanitarians said on
Tuesday.”
From
big pharma to smaller players, stocks in the sector are making headlines as the
outbreak continues. Biotech and biodefense stocks focusing on infectious
diseases like Ebola can be highly speculative and the sector has already
experienced volatility.
Paid News
Dissemination of behalf of AEMD
Read this news, featuring AEMD in full at
https://www.investorideas.com/CO/AEMD/news/2026/06261-biotech-ebola-vaccines-therapeutics.asp
Soligenix
(NASDAQ:SNGX)
a late-stage biopharmaceutical company focused on developing and
commercializing products to treat rare diseases where there is an unmet medical
need, reported June 8th that the Coalition for Epidemic Preparedness
Innovations (CEPI) has announced a call for proposal for vaccine development
for Bundibugyo virus (BDBV) with applications due June 12, 2026. Soligenix, in
collaboration with Axel Lehrer, PhD, Professor in the Department of Tropical
Medicine, Medical Microbiology and Pharmacology at the John A. Burns School of
Medicine, University of Hawaiʻi at Mānoa, has previously developed bivalent and
trivalent thermostable vaccines, constructed from antigens against Ebola virus,
Sudan virus and Marburg virus and the CoVaccine HT™ adjuvant, demonstrating
thermostability,
immunogenicity
and durable efficacy in non-human primates. This work, combined with previous
and ongoing work in Dr. Lehrer's laboratory that has demonstrated platform
compatibility of the key Bundibugyo virus antigen, will form the basis of an
application to CEPI enabling rapid development of a protein-based thermostable
subunit vaccine for BDBV.
"Our
filovirus vaccines have demonstrated broad and robust immune responses in mice
and up to 100% protection in non-human primates," stated Dr. Lehrer.
"Further, we have developed thermostable vaccine formulations in
collaboration with Soligenix, demonstrating extended stability that is
particularly relevant for the use of these vaccines in virus-endemic countries
in Africa, as well as in the context of strategic national stockpiles and
preparations for potential larger outbreaks and pandemics. A single-vial
subunit vaccine that can be shipped at ambient temperatures and then needs to
only be reconstituted with sterile water immediately prior to use has the
potential to improve vaccination efforts globally by simplifying storage and
distribution logistics not only as a stand-alone vaccine, but also as a
practical add-on booster broadening immunity in persons previously or
concurrently vaccinated with other vaccines. We look forward to submitting this
application with the aim of rapidly advancing the BDBV vaccine and the
multivalent platform in general."
Aethlon
Medical, Inc. (Nasdaq:
AEMD), a medical therapeutic company focused on
developing products to treat cancer and life-threatening infectious diseases recently
announced that it is actively monitoring
developments related to the current Bundibugyo Ebola virus outbreak in Democratic
Republic of the Congo and Uganda, and remains prepared to engage with global
healthcare and regulatory authorities regarding the potential investigational
use of its Hemopurifier® technology.
Aethlon’s
Hemopurifier is an investigational medical device designed to remove enveloped
viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire
strain) outbreak, the Hemopurifier was successfully administered to a critically
ill Ugandan physician treated at Frankfurt University Hospital under
emergency-use circumstances.
At
the time Hemopurifier therapy was initiated, the physician was unconscious and
suffering from multiple organ failure requiring mechanical ventilation,
vasopressor support and continuous dialysis. Following a single 6.5-hour
Hemopurifier treatment, the patient’s viral load reportedly declined from
approximately 400,000 Ebola virus copies per milliliter of blood to
approximately 1,000 copies per milliliter of blood. The Ebola virus
subsequently became undetectable five days following treatment. Testing
performed after this treatment indicated that the Hemopurifier captured Ebola
virus during therapy; quantitative estimates reported at the time, were approximately
242 million virions. The patient ultimately made recovered and returned home to
Uganda.
In
its recent earnings conference call, Aethlon noted that it has shared
information regarding its Ebola-related research, clinical experience, and
regulatory status with the World Health Organization's R&D Blueprint Expert
Panel and the National Emerging Special Pathogens Training and Education Center
(NETEC), which works closely with the 13 U.S. regional special pathogen
treatment centers that would treat an Ebola patient in the United States should
one occur.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced in May that maftivimab, the most potent neutralizing antibody
included in Inmazeb® (maftivimab, atoltivimab and odesivimab-ebgn), has been
recommended by the World Health Organization’s (WHO) Therapeutics Advisory
Group to be prioritized for evaluation in clinical trials of investigational
treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad
activity in vitro against multiple Ebola species, including Bundibugyo.
The trial pertains to the WHO’s recent declaration
that the current outbreak of Ebola disease caused by Bundibugyo virus in the
Democratic Republic of the Congo (DRC) and Uganda constitutes a public health
emergency of international concern. WHO is now working closely with the
governments of DRC and Uganda to facilitate the implementation of research
evaluations of the prioritized products.
“We are closely coordinating our efforts with the
U.S. Department of Health and Human Services (HHS) and look forward to working
with the World Health Organization and others as clinical evaluation moves ahead,”
said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief
Executive Officer of Regeneron. “Regeneron has a track record of rapidly
delivering important medical solutions during times of global health crisis,
such as the COVID-19 pandemic and multiple Ebola outbreaks, and we know that
independently run and locally executed clinical trials are critical to
developing effective new medicines in such situations.”
Inmazeb is already approved by the U.S. Food and
Drug Administration for the treatment of infection caused by Orthoebolavirus
zairense, also known as Zaire ebolavirus, in adult and pediatric patients,
including neonates born to infected mothers. Maftivimab is the most potent
virus-neutralizing component of Inmazeb and has demonstrated broad neutralizing
activity in laboratory studies against Bundibugyo ebolavirus; it has not yet
been tested in vivo as a monotherapy against this distinct Ebola virus.
Maftivimab has been administered to hundreds of human patients as a component of
Inmazeb, which has demonstrated an acceptable safety profile. Since 2018,
Inmazeb has been offered by Regeneron at no cost under a compassionate use
protocol to infected persons in countries experiencing an Orthoebolavirus
zairense outbreak, including the DRC and Guinea.
On
June 1, Moderna, Inc. (NASDAQ:MRNA) announced an expanded collaboration with the
Coalition for Epidemic Preparedness Innovations (CEPI) to advance the
development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a
cause of Ebola virus disease for which there are currently no licensed vaccines
indicated.
Under
the agreement, CEPI has committed up to US $50 million to support preclinical
development and Phase 1 clinical testing of Moderna's investigational BDBV
vaccine candidate. The funding will also support parallel manufacturing
activities, enabling doses to be produced while clinical evaluation is underway
and positioning the program to rapidly advance into large-scale Phase 2/3
trials should the Phase 1 safety and immunogenicity data support further
development.
The
vaccine candidate is being developed using Moderna's mRNA platform, the same
technology that demonstrated rapid development, scalability, and global
deployment capabilities during the COVID-19 pandemic. The program also builds
on Moderna's existing research and development efforts in filoviruses,
including Ebola-related viruses.
The
collaboration further expands Moderna's longstanding strategic collaboration
with CEPI, which is focused on accelerating the development of vaccines and
other countermeasures against epidemic and pandemic threats.
"At
Moderna, we believe our mRNA platform can play an important role in responding
rapidly to emerging infectious disease threats," said Stéphane Bancel,
Chief Executive Officer of Moderna. "We are proud to expand our strategic
collaboration with CEPI to advance a potential vaccine candidate against Bundibugyo
ebolavirus, leveraging our established technology and experience in filovirus
vaccine development. We will move with urgency and scientific rigor to support
the response and help bring a potential vaccine closer to the communities that
need it most."
By
combining CEPI's funding and expertise in epidemic preparedness with Moderna's
mRNA platform and manufacturing capabilities, the collaboration aims to
accelerate the development of a potential vaccine that could help strengthen
global readiness against future Ebola outbreaks.
"With
Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts
in the race against this deadly disease," said Dr. Richard Hatchett, CEO
of CEPI. "CEPI's urgent funding and support aims to advance safe,
effective vaccines to help control this epidemic."
Disclaimer/Disclosure: Disclaimer:
Biotech and biodefense stocks focusing on infectious diseases can be highly
speculative and carry significant volatility. Aethlon Medical, Inc. (AEMD) is a paid
featured medical tech stock
on Investor ideas More
disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. More
disclosure: Contact management and IR of
each company directly regarding specific questions.
Research biotech stocks at Investorideas.com:
https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp
About Investorideas.com – Where you find the best investing
ideas
Investorideas.com
is a trusted platform for retail investors, serving as a hub for innovative
investing ideas for over 25 years. Known for its pioneering coverage of sectors
like mining, cleantech, defense, and water stocks, the company and its
executives have been featured in high-profile media outlets for its expertise.
Investorideas.com is always at the forefront of investment trends, offering
coverage of diverse industries such as Al, mining, and tech. With a mission to
empower investors, the company provides breaking news, sector-focused articles,
podcasts, and exclusive interviews with leading experts. In addition, its
award-winning branded content, Al-driven short videos, and podcasts highlight
key investing insights and feature prominent industry leaders.
Investor Ideas digital advertising and guest posts service :
https://www.investorideas.com/Advertise/
Follow
us on X @investorideas @stocknewsbites
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
Investorideas on YouTube https://www.youtube.com/c/Investorideas
Join
our free Telegram community
https://t.me/+o8DxSAgeNCk2ZGVh
Contact us for more
info
Call
800 665 0411
